Zheng Wenjie, Xiao Hong, Liu Huan, Zhou Yue
Department of Orthopedics, Xinqiao Hospital, The Third Military Medical University, Chongqing, China.
APMIS. 2015 Feb;123(2):102-7. doi: 10.1111/apm.12311. Epub 2014 Sep 25.
Accumulating bodies of evidence indicate that immune dysregulation plays a key role in the development of osteosarcoma (OS). Programmed death 1 (PD-1) is a surface receptor expressed on activated and exhausted T cells, which mediate T-cell inhibition upon binding with its ligand. Researches on PD-1 and OS remain extremely limited. Here, we investigated whether PD-1 could be involved in the development of OS. Expression of PD-1 was measured by flow cytometry on peripheral CD4+ and CD8+ T cells from 56 OS cases and 42 healthy controls. Data revealed that percentages of PD-1 were significantly upregulated on both peripheral CD4+ and CD8+ T cells from OS patients (p < 0.001 and p < 0.001, respectively). Patients with different tumor locations did not present obvious variations in PD-1 level. However, patients with metastasis showed significantly higher level of PD-1 on CD4+ T cells than those without metastasis (p < 0.001). Furthermore, PD-1 expression on CD4+ T cells started to increase in stage III, whereas PD-1 expression on CD8+ T cells started to increase in stage II. In addition, patients with pathological fracture were observed to have elevated PD-1 on both CD4+ and CD8+ T cells. These data suggest that PD-1 is involved in the pathogenesis of OS, especially in the progression of disease.
越来越多的证据表明，免疫失调在骨肉瘤（OS）的发展中起关键作用。程序性死亡1（PD-1）是一种在活化和耗竭的T细胞上表达的表面受体，其与配体结合后介导T细胞抑制。关于PD-1与OS的研究仍然极为有限。在此，我们研究了PD-1是否参与OS的发展。通过流式细胞术检测了56例OS患者和42例健康对照外周血CD4+和CD8+T细胞上PD-1的表达。数据显示，OS患者外周血CD4+和CD8+T细胞上PD-1的百分比均显著上调（分别为p<0.001和p<0.001）。不同肿瘤部位的患者PD-1水平无明显差异。然而，有转移的患者CD4+T细胞上的PD-1水平显著高于无转移的患者（p<0.001）。此外，CD4+T细胞上的PD-1表达在III期开始增加，而CD8+T细胞上的PD-1表达在II期开始增加。另外，观察到发生病理性骨折的患者CD4+和CD8+T细胞上的PD-1均升高。这些数据表明，PD-1参与了OS的发病机制，尤其是在疾病进展过程中。
